AEGEAN Study Shows Benefit of Combination Based Immunotherapy for NSCLC
By Alice GoodmanMay 10, 2023 Patients with Treatment-naive resectable non-small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and durvalumab monotherapy in the adjuvant showed improved event-free survival …
AEGEAN Study Shows Benefit of Combination Based Immunotherapy for NSCLC Read More